A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

Ruth A. Karron; Peter F. Wright; Susan L. Hall; Mamodikoe Makhene; Juliette Thompson; Barbara A. Burns; Sharon Tollefson; Mark C. Steinhoff; Modena H. Wilson; Denos O. Harris; Mary Lou Clements; Brian R. Murphy

doi:10.1093/infdis/171.5.1107

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

Ruth A. Karron, Peter F. Wright, Susan L. Hall, Mamodikoe Makhene, Juliette Thompson, Barbara A. Burns, Sharon Tollefson, Mark C. Steinhoff, Modena H. Wilson, Denos O. Harris, Mary Lou Clements, Brian R. Murphy

Bloomberg School of Public Health

Research output: Contribution to journal › Article › peer-review

109 Scopus citations

Abstract

The safety, infectivity, immunogenicity, transmissibility, and phenotypic stability of an intranasal bovine parainfluenza virus type 3 (BPIV-3) candidate vaccine was evaluated in a randomized, double-blind, placebo-controlled trial. Of human parainfluenza virus type 3 (HPIV-3)-seronegative children, 92% were infected, and 92% developed a serum hemagglutination-inhibiting (HAI) antibody response to BPIV-3 and 61% to HPIV-3. Geometric mean HAI titers were 1:40 to BPIV-3 and 1:16 to HPIV-3. In studies to evaluate vaccine transmissibility, none of 14 placebo recipients in close contact with 14 vaccinees shed BPIV-3. BPIV-3 isolates from seronegative vaccinees retained the attenuation phenotype when tested in rhesus monkeys. Although it is difficult to evaluate the safety and immunogenicity of such a vaccine in an open population of children who frequently become infected with HPIV-3, it appears that the live BPIV-3 vaccine is attenuated, infectious, immunogenic, poorly transmissible, and phenotypically stable and warrants further evaluation as a candidate vaccine in infants and children.

Original language	English (US)
Pages (from-to)	1107-1114
Number of pages	8
Journal	Journal of Infectious Diseases
Volume	171
Issue number	5
DOIs	https://doi.org/10.1093/infdis/171.5.1107
State	Published - May 1995

ASJC Scopus subject areas

Immunology and Allergy
Infectious Diseases

Access to Document

10.1093/infdis/171.5.1107

Cite this

Karron, R. A., Wright, P. F., Hall, S. L., Makhene, M., Thompson, J., Burns, B. A., Tollefson, S., Steinhoff, M. C., Wilson, M. H., Harris, D. O., Clements, M. L., & Murphy, B. R. (1995). A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. Journal of Infectious Diseases, 171(5), 1107-1114. https://doi.org/10.1093/infdis/171.5.1107

Karron, RA, Wright, PF, Hall, SL, Makhene, M, Thompson, J, Burns, BA, Tollefson, S, Steinhoff, MC, Wilson, MH, Harris, DO, Clements, ML & Murphy, BR 1995, 'A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children', Journal of Infectious Diseases, vol. 171, no. 5, pp. 1107-1114. https://doi.org/10.1093/infdis/171.5.1107

@article{dd2ec7b062bb4442afce4f3ae0555cef,

title = "A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children",

abstract = "The safety, infectivity, immunogenicity, transmissibility, and phenotypic stability of an intranasal bovine parainfluenza virus type 3 (BPIV-3) candidate vaccine was evaluated in a randomized, double-blind, placebo-controlled trial. Of human parainfluenza virus type 3 (HPIV-3)-seronegative children, 92% were infected, and 92% developed a serum hemagglutination-inhibiting (HAI) antibody response to BPIV-3 and 61% to HPIV-3. Geometric mean HAI titers were 1:40 to BPIV-3 and 1:16 to HPIV-3. In studies to evaluate vaccine transmissibility, none of 14 placebo recipients in close contact with 14 vaccinees shed BPIV-3. BPIV-3 isolates from seronegative vaccinees retained the attenuation phenotype when tested in rhesus monkeys. Although it is difficult to evaluate the safety and immunogenicity of such a vaccine in an open population of children who frequently become infected with HPIV-3, it appears that the live BPIV-3 vaccine is attenuated, infectious, immunogenic, poorly transmissible, and phenotypically stable and warrants further evaluation as a candidate vaccine in infants and children.",

author = "Karron, {Ruth A.} and Wright, {Peter F.} and Hall, {Susan L.} and Mamodikoe Makhene and Juliette Thompson and Burns, {Barbara A.} and Sharon Tollefson and Steinhoff, {Mark C.} and Wilson, {Modena H.} and Harris, {Denos O.} and Clements, {Mary Lou} and Murphy, {Brian R.}",

note = "Funding Information: Financial support: National Institutes of Health (AI-15095 and AI-05050).",

year = "1995",

month = may,

doi = "10.1093/infdis/171.5.1107",

language = "English (US)",

volume = "171",

pages = "1107--1114",

journal = "Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

AU - Karron, Ruth A.

AU - Wright, Peter F.

AU - Hall, Susan L.

AU - Makhene, Mamodikoe

AU - Thompson, Juliette

AU - Burns, Barbara A.

AU - Tollefson, Sharon

AU - Steinhoff, Mark C.

AU - Wilson, Modena H.

AU - Harris, Denos O.

AU - Clements, Mary Lou

AU - Murphy, Brian R.

N1 - Funding Information: Financial support: National Institutes of Health (AI-15095 and AI-05050).

PY - 1995/5

Y1 - 1995/5

N2 - The safety, infectivity, immunogenicity, transmissibility, and phenotypic stability of an intranasal bovine parainfluenza virus type 3 (BPIV-3) candidate vaccine was evaluated in a randomized, double-blind, placebo-controlled trial. Of human parainfluenza virus type 3 (HPIV-3)-seronegative children, 92% were infected, and 92% developed a serum hemagglutination-inhibiting (HAI) antibody response to BPIV-3 and 61% to HPIV-3. Geometric mean HAI titers were 1:40 to BPIV-3 and 1:16 to HPIV-3. In studies to evaluate vaccine transmissibility, none of 14 placebo recipients in close contact with 14 vaccinees shed BPIV-3. BPIV-3 isolates from seronegative vaccinees retained the attenuation phenotype when tested in rhesus monkeys. Although it is difficult to evaluate the safety and immunogenicity of such a vaccine in an open population of children who frequently become infected with HPIV-3, it appears that the live BPIV-3 vaccine is attenuated, infectious, immunogenic, poorly transmissible, and phenotypically stable and warrants further evaluation as a candidate vaccine in infants and children.

AB - The safety, infectivity, immunogenicity, transmissibility, and phenotypic stability of an intranasal bovine parainfluenza virus type 3 (BPIV-3) candidate vaccine was evaluated in a randomized, double-blind, placebo-controlled trial. Of human parainfluenza virus type 3 (HPIV-3)-seronegative children, 92% were infected, and 92% developed a serum hemagglutination-inhibiting (HAI) antibody response to BPIV-3 and 61% to HPIV-3. Geometric mean HAI titers were 1:40 to BPIV-3 and 1:16 to HPIV-3. In studies to evaluate vaccine transmissibility, none of 14 placebo recipients in close contact with 14 vaccinees shed BPIV-3. BPIV-3 isolates from seronegative vaccinees retained the attenuation phenotype when tested in rhesus monkeys. Although it is difficult to evaluate the safety and immunogenicity of such a vaccine in an open population of children who frequently become infected with HPIV-3, it appears that the live BPIV-3 vaccine is attenuated, infectious, immunogenic, poorly transmissible, and phenotypically stable and warrants further evaluation as a candidate vaccine in infants and children.

UR - http://www.scopus.com/inward/record.url?scp=0028957192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028957192&partnerID=8YFLogxK

U2 - 10.1093/infdis/171.5.1107

DO - 10.1093/infdis/171.5.1107

M3 - Article

C2 - 7751684

AN - SCOPUS:0028957192

SN - 0022-1899

VL - 171

SP - 1107

EP - 1114

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

IS - 5

ER -

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this